Engin ONAN, Hikmet AKKIZ, Macit Umran SANDIKCI, Oğuz ÜSKÜDAR, Agah Bahadır ÖZTÜRK

Hepatoselüler karsinomda serum mikroRNA-122'nin önemi

Amaç: Bu çalışmanın amacı, hepatoselüler karsinomda dolaşımdaki mikroRNA-122'nin (miR-122) biyobelirteç olarak potansiyelini araştırmaktır. Gereç ve Yöntem: Bu çalışmada, dolaşımdaki miR-122 seviyeleri, hepatoselüler karsinomun farklı klinik evreleri olan hastalarda gerçek zamanlı polimeraz zincir reaksiyonu ile ölçülmüştür. Ayrıca, bu veriler ile serum miR-122 seviyeleri arasındaki korelasyonu gözlemlemek için diğer laboratuvar ve klinik veriler de değerlendirilmiştir. Bulgular: Hepatoselüler karsinom hastalarında serum miR-122 seviyeleri kontrol grubuna göre anlamlı olarak yüksek bulundu. (medyan miR-122 (min. - maks.); hastalar: 0,0104 (0-0,262); kontroller: 0,00187 (0-0,100), p

Anahtar Kelimeler:

Hepatoselüler karsinom, serum microRNA-122., microRNA-122

Importance of circulating microRNA-122 for hepatocellular carcinoma

Purpose: The main purpose of our study is to research the potential of circulating microRNA-122 (miR-122)as a marker for hepatocellular carcinoma. Materials and Methods: Circulating miR-122 levels were measured by real-time polymerase chain reaction in patients with varied stages of hepatocellular carcinoma. In addition, various other laboratory and clinical data of the participants were evaluated in order to observe the correlation between these data and serum miR-122 levels. Results: Serum miR-122 levels were found significantly higher in hepatocellular carcinoma patients compared to the control group. (median miR-122 (min. – max.); patients: 0.0104 (0-0.262); controls: 0.00187 (0-0.100), p

Keywords:

Hepatocellular carcinoma, microRNA-122, circulating microRNA-122,

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-50.
3. Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep. 2019;6:104-11.
4. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604.
5. Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17.
6. Zinkin NT, Grall F, Bhaskar K et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008;14:470-7.
7. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120:21-4.
8. Zhang HH, Wang XJ, Li GX, Yang E, Yang NM. Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol. 2007;13:2883-8.
9. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009;9:703-11.
10. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
11. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721-6.
12. Ladeiro Y, Couchy G, Balabaud C et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatol. 2008;47:1955-63.
13. Varnholt H, Drebber U, Schulze F et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatol. 2008;47:1223-32.
14. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526-36.
15. Kutay H, Bai S, Datta J et al. Downregulation of miR122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99:671-8.
16. Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25:2537-45.
17. Xu J, Wu C, Che X et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50:136-42.
18. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011;6:e28486.
19. Bignotti E, Calza S, Tassi RA et al. Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. J Cell Mol Med. 2016;20:2341-8.
20. Masè M, Grasso M, Avogaro L et al. Selection of reference genes is critical for miRNA expression analysis in human cardiac tissue. A focus on atrial fibrillation. Sci Rep. 2017;7:41127.
21. Wang K, Zhang S, Marzolf B et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009;106:4402- 7.
22. Köberle V, Kronenberger B, Pleli T et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49:3442-9.
23. Kojima K, Takata A, Vadnais C et al. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun. 2011;2:338.
24. Tsai WC, Hsu PW, Lai TC et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatol. 2009;49:1571-82.
25. Yang X, Sun L, Wang L, Yao B, Mo H, Yang W. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4. Biomed Pharmacother. 2019;118:109386.
26. Amr KS, Elmawgoud Atia HA, Elazeem Elbnhawy RA, Ezzat WM. Early diagnostic evaluation of miR122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes Dis. 2017;4:215-21.
27. Cakmak HA, Demir M. MicroRNA and cardiovascular diseases. Balkan Med J. 2020;37:60-71.